EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 28 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $273,000 | -28.0% | 4,579 | -4.8% | 0.00% | -50.0% |
| Q2 2017 | $379,000 | -63.5% | 4,809 | -61.6% | 0.00% | -50.0% |
| Q1 2017 | $1,038,000 | -34.4% | 12,512 | -37.3% | 0.00% | -42.9% |
| Q4 2016 | $1,583,000 | +7.0% | 19,946 | -5.6% | 0.01% | +16.7% |
| Q3 2016 | $1,479,000 | +76.3% | 21,131 | -2.3% | 0.01% | +50.0% |
| Q2 2016 | $839,000 | +23.9% | 21,631 | +29.5% | 0.00% | +33.3% |
| Q1 2016 | $677,000 | -63.3% | 16,708 | -19.7% | 0.00% | -62.5% |
| Q4 2015 | $1,845,000 | +52.1% | 20,812 | +27.0% | 0.01% | +60.0% |
| Q3 2015 | $1,213,000 | -7.2% | 16,386 | +1.4% | 0.01% | 0.0% |
| Q2 2015 | $1,307,000 | +847.1% | 16,164 | +49.2% | 0.01% | +400.0% |
| Q1 2014 | $138,000 | – | 10,834 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |